Synechron Implements Calypso Solution For SIX, Swiss Financial Services Provider and Infrastructure Operator for the Swiss Stock Exchange
Synechron is proud to share in the success of the launch of the brand new Calypso implementation for SIX, the Swiss financial services provider that also operates the Swiss Stock Exchange. Synechron was chosen as systems integrator in collaboration with Calypso for the Swiss Stock Exchange’s SFR (Securities Finance Renewal) project which aims to modernize the post-trade services process that the exchange, as a triparty agent, offers its clients.
This innovative project (the first Calypso implementation to manage a triparty agent activity) is divided into two phases and delivery on 15 June 2020 marks the end of phase 1.
The project includes teams from SIX, Calypso and Synechron working in close collaboration and with Synechron notably using its European Delivery Center in Novi Sad (Serbia) to provide some of the team members.
« As a certified Calypso partner, Synechron gave us access to its considerable expertise and knowledge of Calypso’s methodologies and best practices and a strong working relationship with the vendor, which was a key success factor for this extremely important project » explained Nerin Demir, Head of Securities Finance & Market Data at SIX.
A full and innovative implementation
From the outset, Synechron and Calypso consultants were present at all stages of the project: development, implementation, test campaigns with clients, launch and production support. This teamwork made agile delivery of the Calypso implementation possible, using development and configuration best practices to ensure easy maintenance of the platform for SIX.
In addition to the development and configuration teams, Synechron also set up a dedicated quality team in Serbia, allowing the other consultants to focus on the project’s business aspects. Synechron also participated in some front-end web development for external users.
Commenting on the launch, Valerio Roncone, Head Future Business, Securities & Exchanges, SIX said:
« The collateral management process has – until now – been fragmented and unwieldly for many stakeholders. With our new Triparty Agent, we have created a hub that will harness the power of automation and intelligent data usage to give repo professionals, traders, treasury professionals, and other stakeholders full control over their collateral. Through this technology, manual tasks like monitoring and adjusting will no longer require attention, and professionals can focus on what matters: driving efficiency, accountability, and accuracy. »
Key success factors
One of the project’s key factors for success is the close collaboration between the three companies: SIX, Calypso and Synechron. Also, for the integrator and vendor, working hand in hand is crucial when it comes to solving problems that inevitably arise in such a major project.
Synechron’s Calypso Center of Excellence was also made available for essential training to onboard new starters. Regular short-distance trips between Zurich and Serbia and daily video-conferencing sessions with no time difference helped develop team spirit rapidly among all the participants.
« We, together with the Swiss Stock Exchange and backed by our partner Calypso, are very proud to have contributed to the success of this innovative and major project for the Swiss financial infrastructure. The project combines all our financial software implementation expertise acquired over the years. We are confident and excited about phase 2 of the project which has already begun » added François-Bernard Mizrahi, Managing Director of Synechron.
SIX operates and develops infrastructure services in the Securities & Exchanges, Banking Services and Financial Information business units with the aim of raising efficiency, quality and innovative capacity across the entire value chain of the Swiss financial center. The company is owned by its users (122 banks). With a workforce of some 2,600 employees and a presence in 20 countries, it generated operating income of CHF 1.13 billion and Group net profit of CHF 120.5 million in 2019.
About The Swiss Stock Exchange.
The Swiss Stock Exchange combines the dynamism of Europe’s 2nd biggest stock exchange* with the stability and reliability of one of the industry’s most respected post-trade service providers. Covering the entire securities value chain, The Swiss Stock Exchange is your single source for Listing, Trading and Post-Trade services, as well as the gateway to the future of value exchange with the SIX Digital Exchange.
It offers outstanding liquidity in trading of Swiss securities and connects companies from around the world with international investors and trading participants. The Swiss Stock Exchange blends the geographical advantages of the Swiss financial center with world-class services making it the ideal listing location for companies of every origin, size and sector.
The Swiss Stock Exchange offers comprehensive services in the areas of securities trading, clearing, settlement, Swiss & international custody, securities finance, collateral management and tax services. The Swiss Stock Exchange is part of SIX which also owns the Spanish BME and provides global financial information and Swiss banking services.
*By free float market cap as at 1 April 2020
Synechron is a leading Digital IT Consulting firm for financial services, Accelerating Digital for financial institutions by providing innovative solutions to the financial services industry through its three main business focus areas: digital, business consulting, and technology. Based in New York, the company has 18 offices around the globe, with over 8,000 employees producing over $500+M in annual revenue. For more information please visit the our LinkedIn community.
SWISS STOCK EXCHANGE and SIX Contact
Head of Marketing
Project Manager for SFR Project at SIX
Head of Calypso Center of Excellence
Director, Global Marketing & Communication
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom